- Home
- DHF vs GOSS Comparison
DHF vs GOSS Comparison
Compare DHF & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHF
- GOSS
- Stock Information
- Founded
- DHF 1998
- GOSS 2015
- Country
- DHF United States
- GOSS United States
- Employees
- DHF N/A
- GOSS N/A
- Industry
- DHF Finance Companies
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- DHF Finance
- GOSS Health Care
- Exchange
- DHF Nasdaq
- GOSS Nasdaq
- Market Cap
- DHF 174.6M
- GOSS 188.6M
- IPO Year
- DHF N/A
- GOSS 2019
- Fundamental
- Price
- DHF $2.40
- GOSS $0.84
- Analyst Decision
- DHF
- GOSS Strong Buy
- Analyst Count
- DHF 0
- GOSS 4
- Target Price
- DHF N/A
- GOSS $7.50
- AVG Volume (30 Days)
- DHF 451.1K
- GOSS 1.5M
- Earning Date
- DHF 01-01-0001
- GOSS 05-06-2025
- Dividend Yield
- DHF 7.65%
- GOSS N/A
- EPS Growth
- DHF N/A
- GOSS N/A
- EPS
- DHF N/A
- GOSS N/A
- Revenue
- DHF N/A
- GOSS $114,701,000.00
- Revenue This Year
- DHF N/A
- GOSS N/A
- Revenue Next Year
- DHF N/A
- GOSS $172.31
- P/E Ratio
- DHF N/A
- GOSS N/A
- Revenue Growth
- DHF N/A
- GOSS N/A
- 52 Week Low
- DHF $2.06
- GOSS $0.50
- 52 Week High
- DHF $2.39
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- DHF 42.17
- GOSS 37.58
- Support Level
- DHF $2.25
- GOSS $0.80
- Resistance Level
- DHF $2.43
- GOSS $0.88
- Average True Range (ATR)
- DHF 0.07
- GOSS 0.10
- MACD
- DHF 0.00
- GOSS -0.01
- Stochastic Oscillator
- DHF 54.55
- GOSS 20.24
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.